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Abstract 
Drug misuse in prisons contributes to increased disruption and violence and negatively impacts prisoner 
safety, rehabilitation, and recovery. Synthetic cannabinoid receptor agonists (SCRAs), colloquially 
known as ‘spice’, are infused into papers and are of particular concern in a prison setting where they are 
commonly vaped. Methods for the qualitative and quantitative analysis of SCRA infused papers, 
including impurity profiling, were developed and applied to 354 individual seized paper samples 
originating from 168 seizures from three Scottish prisons. Of these samples, 41% (146 samples from 
101 seizures) contained at least one SCRA and multiple SCRAs were detected on 23% of these papers. 
Concentrations ranged from <0.05-1.17 mg/cm2 paper, representing the first reported quantitative data 
for SCRA infused papers. An evolution in the SCRAs detected was demonstrated; 5F-MDMB-PINACA 
(5F-ADB) predominated until late 2018 after which time 5F-MDMB-PICA and 4F-MDMB-BINACA 
became increasingly more prevalent followed by the arrival of MDMB-4en-PINACA in June 2019. A 
typical infused paper or card dosage unit is an approximately 1cm2 piece torn from larger sheets 
circulating within the prison. Concentration mapping data from two seized paper samples demonstrated 
that SCRA concentrations across larger papers were highly variable (0.47-2.38 mg/cm2 paper) making 
consistent dosing by users, and representative sampling by laboratory analysts, difficult. Near real-time 
qualitative and quantitative information on SCRAs circulating in prisons can act as an early warning 
system for SCRA compounds emerging on the wider illicit market, inform the methods used to detect 
them and limit supply, and provide information to support harm reduction measures. 
1
1. Introduction
The reduction of drug misuse and drug harms in prisons has been described as one of the great challenges
facing the criminal justice system1. Drug misuse contributes to increasing levels of disruption, violence,
and crime and has a negative impact on prisoner safety, rehabilitation, and recovery2-4. The increased
prevalence of potent new psychoactive substance (NPS) use in prisons in the last decade is of particular
concern1,2,5 and is widespread across Europe6. The prevalence of Synthetic Cannabinoid Receptor
Agonists (SCRAs), often referred to colloquially and collectively as ‘spice’, in prisons in England and
Wales is well established and can be described as endemic and entrenched2, 5,7-14. The actual substances
will vary and change over time, presenting analytical challenges for field deployed detection systems
and laboratories tasked with detecting and quantifying them for judicial, intelligence, and harm-
reduction purposes.
SCRAs are a structurally diverse class of compounds that interact with human cannabinoid type 1 and 
type 2 G-Protein Coupled Receptors (GPCRs), CB1 and CB215-19. They vary widely in their potency and 
efficacy20-22 as a result of differences in their structural conformation, including chirality23. Their 
diversity is due, in part, to the increased online availability of published research studies and patents 
describing their synthesis, in vitro potency and efficacy, and biological effects; the availability of 
precursor materials; increasing understanding of their structure-activity relationships by producers and 
suppliers; and as a response to the implementation of national and international legislation designed to 
control their production, prevalence, and use, and in particular, their use in prisons16.  
SCRAs first appeared in the scientific literature and patents as research tools and potential therapeutic 
agents, with research in this area continuing today16. SCRAs were first formally identified in herbal 
blends sold for recreational use (commonly referred to as legal highs) in 200824. Until 2016, such 
normally inert herbal materials infused or sprayed with SCRAs were openly sold by retailers, often 
referred to as ‘head shops’ in the United Kingdom (UK) and elsewhere25, as well as being sold by online 
vendors.  
In 2009 and 2013, two consecutive amendments to the Misuse of Drugs Act (MDA) 1971, the principle 
legislation in the United Kingdom (UK) for the control of drugs with a potential for misuse and harm, 
were enacted26,27 defining analogue controls for SCRAs designed to make the production, possession, 
and supply of a large number of structurally related compounds illegal. Although helpful in reducing 
the prevalence of the SCRAs defined in the legislation, this effectively led to a ‘cat and mouse’ game 
between producers, sellers, and legislators. Producers continued to alter SCRA chemical structures to 
circumvent the legislation and/or evade detection16. This, as well as the enactment of other national and 
international legislative controls, has led to a proliferation of new SCRA compounds, with 260 SCRAs 
being reported to the United Nations Office for Drugs and Crime (UNODC) by December 201828 and 
over 180 to the EU Early Warning System29. The rate of the emergence of new compounds may be 
slowing29, but there has been a general trend of increasing potency as the understanding of SCRA 
structure-activity relationships has improved17,18,30,31.  
In an attempt to end the ‘cat and mouse’ game, the Psychoactive Substances Act (PSA) was enacted in 
May 2016 in the UK, making the production, distribution, sale, supply, and possession in custodial 
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institutions (e.g. prisons) of psychoactive substances for human consumption illegal32, irrespective of 
whether or not they were covered by the MDA, 1971. In December 2016, a third SCRA-related 
amendment to the MDA, 1971 ensured the inclusion in the analogue controls of many of the then 
emerging and potent indazole/indole-3-carboxamide based SCRAs which continue to be prevalent 
today19,33. The analogue controls set out in the 2016 amendment were further amended in November 
2019 to reduce the scope of the definition of third generation SCRAs and exclude some compounds that 
were unintentionally controlled in 201634. 
 
The PSA, along with the enforcement of trading standards legislation, effectively led to the cessation of 
the open sale of NPS, including SCRAs26. Whilst clearly reducing the highly visible sale of such 
substances by retailers, the PSA appears to have had a limited effect on their prevalence of use  in some 
user sub-groups, particularly rough-sleeping and prison communities. In Scotland, since the cessation 
of their open sale, the use of SCRAs in the general population appears to have decreased rapidly, but 
their use remains prevalent within the Scottish prison system35. Scottish prison survey data from 2017 
details that 18% of prisoners report having used NPS prior to entering prison, compared to 27% in 2015, 
and of these 70% reported the previous use of SCRAs. In 2017, 18% of prisoners reported using NPS 
whilst in prison, compared to 11% in 2015, and of these, 78% stated they had used SCRAs35. While 
these figures are likely lower than the actual use of NPS and SCRAs in the prisons due to response 
biases, they may demonstrate a shift in the use of NPS in and outside prisons only a year after the 
enactment of the PSA, where the use of NPS prior to entering prisons decreased and their use whilst 
incarcerated increased. 
 
The increase in NPS use has been linked to an increase in violence within Scottish prisons. The Scottish 
Prison Service (SPS) Annual Report 2017/18 reported an increase in serious ‘prisoner on staff’ assaults 
and ‘prisoner on prisoner’ assaults, partially due to increasing numbers of inmates taking NPS (most 
likely SCRAs, but not exclusively, as very little data on the compounds circulating was available at that 
time). There was also a 50% increase in minor or no injury ‘prisoner on staff’ assaults reported from the 
previous year, which ‘appears to be as a result of an increased unpredictability in prisoners’ behaviour’35. 
In addition to increased NPS prevalence, the increase in assaults could be linked to a change in the 
compounds on the SCRA market, as well as a variability in dosing or change in the mode of use. 
 
SCRAs have been detected in herbal material, powders, e-liquids for vaping, and more recently, infused 
papers and other materials11-14, 36-40. Between December 2014 and June 2015, the most prevalent SCRAs 
(and/or their metabolites) detected in both urine samples from prisoners and in drug seizures from 
prisons in England were 5F-AKB48 (1), (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide), also known as 5F-APINACA, and MDMB-CHMICA (2) (methyl 2-[[1-
(cyclohexylmethyl)indole-3-carboxamide]-3,3- dimethylbutanoate)11. Structures of SCRA compounds 
discussed in this study are provided in Figure 1 and numbers in bold parentheses refer to these structures 
throughout the text. The seized SCRA samples were almost exclusively herbal materials sprayed or 
infused with SCRAs. In their report covering the period 2016-2017, the Forensic Early Warning System 
(FEWS), coordinated by the UK Home Office and including the analysis of SCRAs in UK prisons, 
reported the most commonly detected SCRAs to be 5F-MDMB-PINACA (3) (methyl 2-(1-(5-
fluoropentyl)-1H-indazole-3-carboxamide)-3,3-dimethyl-butanoate) and MDMB-CHMICA (2)12 
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illustrating changes in SCRA availability in the market over time, most likely as a result of national and 
international controls. A shift from SCRA impregnated herbal materials (64% of submitted samples) to 
papers and card sprayed with, or soaked in, SCRA containing solutions (14% of submitted samples), 
was observed, likely in response to the implementation of prison smoking bans in England and Wales 
and to facilitate smuggling12. This is similar to the ways in which blotters, also known as ‘tabs’, 
containing hallucinogens, such as d-lysergic acid diethylamide (LSD) and hallucinogenic NPS, have 
been prepared for some time41, although such substances are prepared for sub-lingual use rather than 
smoking or vaping. 
 
In July 2017, the SPS began implementing a smoke-free policy in Scottish prisons, to be in effect by the 
end of 201842. Until the end of December 2018, SPS provided free e-cigarette kits to inmates, and until 
April 2019, inmates could buy e-cigarette kits at a discounted price. Before the smoking ban, inmates 
either smoked herbal material mixed with tobacco or would roll up a piece of the SCRA-saturated paper 
into a cigarette and smoke it, but since the ban, inmates are now known to place pieces of SCRA-infused 
paper between the heating element and the e-liquid cartridge of the e-cigarette. The potential for 
differential effects of inhaling SCRAs in this way, compared to smoking/pyrolysis, is yet to be explored. 
 
As an acknowledged producer and/or exporter of SCRAs43,44, it is noteworthy that when the People’s 
Republic of China legislatively controls a specific compound, that compound quickly disappears from 
the market and is often replaced soon after with new or alternative substances45,46. Early in 2019, the 
State Council of the People’s Republic of China introduced analogue controls for a family of potent 
synthetic opioids (fentanils)47,48, leading the market to respond with the production of a number of 
relatively obscure synthetic opioids from different structural classes. SCRAs continue to be controlled 
on a compound-by-compound basis. As a result, producers have generally responded by introducing 
structurally similar compounds within established structural classes that require minimal changes to 
existing precursors and synthetic routes, whilst retaining a similar potency and/or efficacy. On 29 August 
2018, the State Council of the People’s Republic of China controlled a number of NPS, additional to 
those previously controlled, including eight SCRAs49. These included two of the most prevalent and 
potent SCRAs on the UK market at that time, 5F-MDMB-PINACA (also known as 5F-ADB) (3) and 
AMB-FUBINACA (4)12,16,22,38.  
 
This study reports the development of qualitative and quantitative methods for the detection and 
confirmation of SCRAs in infused papers using Gas Chromatography-Mass Spectrometry (GC-MS), 
and ultra-pressure liquid chromatography with photodiode array and quadrupole time of flight mass 
spectrometry detection (UPLC-PDA-QToF-MS). The methods were applied to the analysis of paper 
samples suspected to be infused with SCRAs seized from three Scottish prisons between June 2018 and 
September 2019. To the best of the authors knowledge, this is the first reported quantitative analysis of 
SCRAs in seized infused papers. The study aims to demonstrate the utility of testing such non-judicial 
samples for monitoring and intelligence purposes and to improve in-field detection, determine 
prevalence, and ultimately to reduce supply and harms as a result of SCRA use in prisons.  





All solvents used were HPLC grade (≥ 99.8% purity) and supplied by either Fisher Chemicals, UK or 
VWR Chemicals, UK. Tridecane (≥ 99% purity) was supplied by Sigma Aldrich, UK. Ultra-high purity 
water (18 MΩcm-1) was obtained using a Milli-Q water purification system (Merck, UK). 
 
2.2. Seized samples 
The samples described in this study were non-judicial samples seized by the Scottish Prison Service. 
Some samples were seized from prisoners directly, as a result of cell searches or were identified during 
screening of incoming mail items using portable ion mobility spectroscopy (IMS) systems. Immediately 
after seizure, samples were placed into tamperproof polythene evidence bags and stored securely. Once 
it was determined that the samples were not required for judicial proceedings, they were set aside for 
this study. Prior to sample uplift the items were reviewed by Scottish Prison Service staff to ensure that 
all personal information present on the seized materials or on the packaging was removed or redacted. 
Samples were uplifted by staff from the Police Scotland Statement of Opinion (STOP) unit and 
transported securely to our laboratory. Examples of the items submitted are shown in Figure 2. 
 
2.3.  Reference Standards 
(S)-5F-MDMB-PICA (5) (methyl N-{[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl}-3-methylvalinate) 
and (S)-AMB-CHMICA (6), also known as (S)-MMB-CHMICA, (methyl 2-{[1-(cyclohexylmethyl)-
1H-indol-3-yl]formamido}-3-methylbutanoate) reference standards were obtained from Chiron, 
Norway (>99% purity). The reference standard for 4F-MDMB-BINACA (7) (methyl 2-[[1-(4-
fluorobutyl)indazole-3-carbonyl]amino]-3,3-dimethyl-butanoate) was originally obtained by extraction 
of the compound from a seized infused paper sample (see Figure 2(a)) using CDCl3, as at the time of 
analysis, no reference standards were commercially available. Approximately 23 mg of 4F-MDMB-
BINACA (7) (>98% purity as assessed by GC-MS and HPLC-DAD) was recovered from this paper and 
identification was confirmed using nuclear magnetic resonance (NMR) and UPLC-QToF-MS (see 
supplementary information for characterisation data). Although the chirality of the extracted material 
was not determined, its achiral identity was confirmed by comparison to an (S)-4F-MDMB-BINACA 
(7) reference standard purchased from Chiron, Trondheim, Norway (>98% purity) once it became 
commercially available. Reference standards for (S)-5F-MDMB-PINACA (3) (99.6% purity); (R)-5F-
MDMB-PINACA (99.6% purity); and (S)-AMB-FUBINACA (4) (>98% purity) were obtained via in-
house synthesis as detailed previously22. In addition, (S)-5F-MDMB-PICA (5), (S)-AMB-CHMICA (6), 
(S)-4F-MDMB-BINACA (7), and (S)-MDMB-4en-PINACA (8) were synthesised as part of this study 
and characterised using GC-MS and NMR spectroscopy (see supplementary information for synthetic 
methods and characterisation data).  
 
2.4.  Calibration Standards 
A series of calibration standards (5-100 µg/mL) were prepared for the quantification of each SCRA 
identified from a 1 mg/mL standard in methanol. 5 mL of the 1 mg/mL standard was made by adding 5 
mg of the SCRA reference standard(s) to a 5 mL volumetric flask. 5 mL of MeOH was added to the 
flask and the mass was noted, so the actual concentration could be calculated. The solution was 
transferred to a vial and immediately sealed. All calibration standards were prepared in 5 mL batches in 
volumetric flasks with 75:25 DCM:MeOH and 0.5 mL of 378 µg/mL tridecane added as an internal 
standard to give a final internal standard concentration of 37.8 µg/mL. In order to limit the air exposure 
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of the standards, the standards were first divided into two GC vials that were immediately capped. A 50 
µL glass syringe was then used to pierce the GC vial cap and withdraw ten 50 µL aliquots which were 
then transferred to amber GC vials fitted with 150 µL GC vial inserts. After the ten standard aliquots 
were prepared, the pierced cap was replaced with a new, unpierced cap for storage. All calibration 
standards were stored in the freezer until use. Standards (and sample extracts) were injected only once 
per vial on the GC-MS. 
 
2.5.   Instrumental Analysis  
NMR spectroscopy for the 4F-MDMB-BINACA (7) extracted from the paper sample was performed 
using a Bruker AVANCE III HD 500 MHz spectrometer (Bruker, Billerica, MA, USA) running under 
TopSpin v.3.2.5 and equipped with a QCI-F cryo-probe at a sample compartment temperature of 20°C. 
Samples were prepared in CDCl3 (~10 mg/mL). NMR spectroscopy of in-house synthesised standards 
reported for the first time in this study (S)-5F-MDMB-PICA (5), (S)-AMB-CHMICA (6), (S)-4F-
MDMB-BINACA (7), and (S)-MDMB-4en-PINACA (8)) was performed using a JEOL ECS-400 NMR 
spectrometer (JEOL, Tokyo, Japan) operating at 400 MHz for 1H-NMR (10 mg/mL in CDCl3) and 13C-
NMR (20 mg/mL in CDCl3). 
 
The GC-MS analysis for both the qualitative and quantitative methods was performed using a 7820A 
gas chromatograph coupled to a 5977E mass spectrometer (Agilent Technologies, Santa Clara, CA, 
USA). Injection mode: 1µL sample injection and used either a 5:1 or 20:1 split into a 1mm internal 
diameter deactivated glass liner pre-packed with quartz wool, injection port temperature: 200ºC, carrier 
gas: He, flow: 1mL/min. Column: HP-5MS, 0.33µm, 0.2 mm x 25 m (Agilent Technologies). GC oven: 
80ºC held for 3min; 40ºC/min to 300ºC held for 3.5 min; transfer line: 295ºC. The mass spectrometer 
operated in electron ionisation (EI) mode. Ionisation conditions: 70eV in full scan mode (50–550 amu), 
ion source: 230ºC, quadrupole: 150ºC. For the quantitation of samples with a combination of 4F-
MDMB-BINACA and MDMB-4en-PINACA, a Selected Ion Monitoring (SIM) method was used 
because these two compounds co-eluted. The same GC method was used as above, but for the MS 
method, the acquisition type was changed to SIM with two time segments. From 3.00 minutes, the MS 
scanned for the ions 71.00 (quantitation) and 57.00 (qualifier) for tridecane with dwell time for each ion 
of 200 ms. From 8.00 minutes, the MS scanned for the ions 219 (quantitation) and 275 (qualifier) for 
4F-MDMB-BINACA and 213 (quantitation) and 301 (qualifier) for MDMB-4en-PINACA with dwell 
time for each ion of 150 ms.  
 
UPLC-PDA-QToF-MS analysis for the qualitative confirmatory analysis of SCRA containing paper 
extracts was performed using an Acquity UPLC instrument with a binary pump, autosampler held at 
4ºC, vacuum degasser, and column oven held at 30ºC coupled to a Xevo QToF-MS (Waters Corporation, 
Milford, MA, USA). Mobile phases used were (A) LC-MS grade water with 0.1% formic acid and (B) 
acetonitrile with 0.1% formic acid. The gradient used was 50:50 A:B from 0.0-4.0 min, 25:75 A:B from 
4.0-5.0 min, 5:95 A:B from 5.0-5.99 min, and 50:50 A:B from 6.0-7.0 min. Flow rate was 0.5 mL/min 
and 2 uL of sample was injected onto a BEH C18 50 × 2.1 mm, 1.7 mm particle size column (Waters 
Corporation, Milford, MA, USA). The QToF was operated in positive ionisation mode with a source 
temperature of 120ºC, a desolvation temperature at 500ºC, and a capillary voltage at 2.25kV. ToF-MS 
analysis for the high-resolution determination of molecular mass was carried out with a collision energy 
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at 6V. MSe acquisition was carried out using collision energies ranging from 0 to 40 V. After the QToF-
MS and MSe data were processed, accurate parent ion fragmentation spectra were obtained using 
MS/MS data acquisition of selected parent ion accurate mass data using collision energies between 10 
and 30V. 
 
2.6. Preliminary Method Development 
Preliminary method development work determined the best solvent for GC-MS qualitative and 
quantitative analysis. Using 10 repeated standard injections from the same vial, dichloromethane 
provided the highest peak area response of all the solvents tested due to its low expansion volume in the 
GC liner, but also had the highest peak area variance due to its volatility (see supplementary 
information). This was due to the evaporation of the dichloromethane from the pierced vial septum 
resulting in the SCRA becoming more concentrated and peak areas increasing over the injection series. 
When the experiment was repeated with multiple single injections from different vials the variance 
decreased dramatically (see supplementary information).   Methanol was chosen as the extraction 
solvent for qualitative analysis, so that samples could subsequently be analysed using UPLC-PDA-
QToF-MS; and 75:25 dichloromethane:methanol (DCM:MeOH) was chosen for quantitative analysis 
and samples in vials would only be injected once. This solvent choice for quantitation ensured that 
compounds with a range of polarities could be extracted, provided good GC-MS precision, and allowed 
the use of methanol as a ‘keeper’ solvent when preparing calibration standards and quality assurance 
samples. While a deuterated standard as an internal standard for the quantitative method would have 
been ideal, at the concentrations used for the quantitation in this study, this would have been 
prohibitively expensive and this method was designed to be widely applicable and low cost. Instead, 
tridecane was used as an internal standard. The tridecane is more nonpolar than the SCRAs and is not 
soluble in MeOH, so when added to 75:25 DCM:MeOH, the tridecane solely resides in the DCM. Since 
DCM is more volatile than MeOH, the DCM along with the tridecane, evaporates at a faster rate than 
the SCRAs. This potential for error was accounted for in the method by sealing all screw cap vials with 
parafilm or ensuring that high quality crimped vials were used.  
 
To verify that three sequential extractions was sufficient to extract SCRAs from the paper samples. 
Three 1x1.5 cm pieces of blank white paper were impregnated with 75 µL of a 1 mg/mL solution of the 
SCRA by suspending the paper between a set of micro forceps between a clamp and dripping the solution 
onto the paper, making sure all of the solution remained on the paper. Once dry, each piece was placed 
in a glass vial and sequentially extracted 5 times using 75:25 DCM:MeOH and 5 minute ultrasonication. 
For each piece, each of the five extractions was placed in a separate GC-MS vial and analysed. The peak 
areas of each extraction were collected, and the percentage of the total peak area determined. Based on 
the three samples extracted for each SCRA, all of the SCRA was extracted after three extractions. The 
data is provided in the supplementary information. 
 
2.7. Qualitative Analysis 
Where the size of the seized paper/card sample permitted, two approximately 1 cm2 samples were cut 
from opposite corners and placed in a glass vial, then 0.25 mL methanol was added and the vial was 
sonicated for five-minutes. The extracts were recovered and analysed using GC-MS. This often 
provided ‘overloaded’ chromatograms where SCRAs were present, allowing the identification of 
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minor SCRA and non-SCRA related components extracted from the paper to be determined as an 
exploration of the potential for SCRA batch profiling, except where SCRAs were present only in low 
concentrations in the extract (equivalent to approx. 5-10 µg/cm2 paper depending on the individual 
SCRA). As no reference standards were available for these minor components and they were often not 
included in the available spectral libraries, they have only been tentatively identified. Sample extracts 
were diluted and the peak areas of the minor components were calculated relative to the major 
component. SCRAs were identified by comparing their retention time and mass spectra to reference 
standards of known origin and by comparison to NIST14, SWGDRUG (v3.5), and Cayman Chemicals 
(versions v04262019 and v09112019) mass spectral libraries with a minimum acceptable reverse 
match value of 850. In the minority of cases where reference standards were not available and/or 
compounds were not present in the spectral libraries, tentative identifications were made by 
elucidation of their molecular structure using fragmentation patterns and visual comparison with 
available online electron impact (EI) ionisation and QToF-MS spectra where available (e.g. Response 
2 Project50, Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) monographs51, 
and The Center for Forensic Science Research and Education (CFSRE) NPS discovery monographs52) 
and/or relevant peer-reviewed literature. All analyte identifications were orthogonally confirmed by 
analysis of either a 10 times dilution of the qualitative analysis extract or the undiluted extracts using 
UHPLC-PDA-QToF-MS in low fragmentation high resolution accurate mass (TOF-MS) and tandem 
(MS/MS) modes.  
 
2.7. Quantitative Analysis 
A 3 mm diameter hole punch sample was collected from previously analysed samples using a 3mm 
biopsy punch, adjacent to where the qualitative sample(s) had been taken. The collected paper was 
placed in a screw-cap glass vial, and sequentially extracted three times in 0.25 mL 75:25 
dichloromethane:methanol (DCM:MeOH), after which the three extracts were combined. The combined 
extracts were weighed and the total volume calculated. A 100 µL aliquot of this extract was diluted to 
200 µL using 80 µL of 75:25 DCM:MeOH and 20 µL of internal standard (tridecane) solution in 75:25 
DCM:MeOH to give a final internal standard concentration of 37.8 µg/mL. The GC-MS vial was then 
sealed with parafilm to prevent any sample evaporation while sitting on the GC-MS sample carousel. 
The remaining original sample was frozen at -20°C. For 5F-MDMB-PICA, AMB-CHMICA, and other 
indole-based SCRAs, a 100 µg/mL standard was run on the GC-MS to check for any degradation 
products as these were seen to increase as the GC liner was used and disappeared when the liner was 
replaced. The GC-MS was calibrated using three sets of a series of SCRA reference standards (5-100 
µg/mL) with tridecane as an internal standard. An average of the three sets of calibration standards were 
used to make the calibration curve. The accuracy of the calibration curve was determined using 
independent calibration check standards at approximately 30 and 85 µg/mL and was approximately 3% 
with a maximum allowable bias of +/- 5%.  
 
To validate the quantitation method, a series of spiked samples were quantitated in order to determine 
the error rate and potential sources of error associated with the method and the consistency of the method 
in calculating the SCRA concentrations of infused papers. To do so, for each SCRA (except MDMB-
4en-PINACA as this analyte was added only in the later stages of this study), seven spiked 1x1.5 cm 
paper pieces were prepared as described above using 75 µL of a 1 mg/mL solution of the SCRA. Each 
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paper was placed in a separate glass vial and taken through the quantitative method described above. 
Three two-fold dilutions of each three-extraction solution were prepared. Three dilutions of each were 
made in order to examine the consistency of the quantitative method and potential error associated with 
the dilution step of the method where the internal standard is added. The three sets of the extraction 
solutions of the seven samples were run on the GC-MS following the appropriate calibration curve and 
check standards. The concentrations were calculated using the same calculations used in the quantitative 
method discussed above and the percent error was calculated (see supplementary information). The 
mean and standard error of the mean (SEM) of the calculated concentrations for the three replicates of 
each sample were calculated as well the mean and SEM of the concentrations across all samples. The 
mean concentrations ranged from 66.13 (-12.6% bias) to 79.20 (+5.1% bias) mg/cm2 paper and the SEM 
ranged from 0.22 to 4.39. See supplementary information for all of the method validation data. 
 
The accuracy of the quantitative method for each batch of samples was checked using a spiked and blank 
paper sample extracted alongside each batch (maximum of 20 samples) in addition to analysis of the 
previously described calibration check standards. An example calibration curve and associated data for 
calibration check standards and the positive batch control samples (spiked paper) is provided in the 
supplementary information. The percent error of the spiked samples during the sample runs ranged from 
1.9-15.2% with an average of 8.6% and median of 11.1%. The estimated percent error of the quantitative 
method determined from the method validation was 15% and is provided as a ± after the calculated 
value. The blank paper sample was a 1x1.5 cm piece of blank white paper that was placed in a glass vial 
and extracted alongside all of the other samples. The calculation of the calibration curve and 
concentrations of samples was performed using an R script. Sample aliquots in inserts within 2 mL 
amber vials were injected only once. Samples with SCRA peak area ratios outside the upper range of 
the calibration curve were reanalysed using a greater dilution of the original sample extract. Samples 
with SCRA peak area ratios below the lower range of the calibration curve were denoted as below the 
limit of quantitation (LOQ), which was calculated for each sample based on the lowest calibration 
standard concentration and the volume of the sample’s three-extraction solution. LOQs ranged from 
0.05-0.09 mg/cm2 paper. 
 
2.8. Mapping SCRA concentrations across seized papers 
Due to the known methods for the illicit preparation of SCRA infused papers and card, SCRA 
concentrations are likely to vary across infused sheets of paper, making consistent dosing by users 
almost impossible. The extent of this variation in seized infused paper samples has not previously been 
investigated. One piece of card, found during qualitative analysis to contain AMB-CHMICA (6), seized 
from Prison 1 on 5 March 2019 and one set of multiple papers which had originally formed a larger 
single sheet of paper, found to contain 5F-MDMB-PICA (5), seized from Prison 1 on 7 March 2019 
were selected for more detailed quantitative analysis using a method adapted from that described by 
Angerer, et al.53. A clean A4 sized piece of tracing paper was printed with a 1 cm2 grid. This grid was 
cut to size, overlaid, and secured onto the paper to be sampled and was used as a guide to collect a 3 
mm diameter punch sample from each grid square. Each 3 mm diameter punch was analysed using the 
quantitative method described above. 
 
2.9. Laboratory prepared SCRA impregnated paper samples 
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To study the variability of SCRA concentrations across papers in a more controlled manner, six 5x5 cm 
(25 cm2) pieces of lined 80 g/m2 paper were prepared and pre-gridded into 1 cm2 sections using a pencil. 
20.1 mg of a previously synthesised22 (R)-5F-MDMB-PINACA (3) standard was dissolved in 
approximately 5 mL of ethanol to give a 4.01 mg/mL solution. The solution was poured into a glass 
beaker and each 5 cm2 piece of paper was laid flat and soaked in the (R)-5F-MDMB-PINACA (3) 
solution for approximately 10 seconds then removed carefully from the solution taking care to keep the 
paper flat as it was removed from the solution. Three papers (A1-A3) were laid flat to dry on a large 
glass tile and the other three pieces were hung up to dry, the top of the paper having been marked in 
pencil prior to soaking in the SCRA solution. The papers were left to dry for 1 hour before each piece 
was cut into the previously gridded 1 cm2 sections (25 samples per paper). Each individual square was 
extracted using the quantitative procedure described above, adapted to account for the difference in 
paper sample size taken.  
 
3. Results and Discussion 
 
3.1.  SCRA market evolution – qualitative and quantitative analysis 
From 1 June 2018 to 27 September 2019, 360 individual seized paper samples originating from 168 
seizures from three Scottish prisons were analysed. Of these samples, 41% (146 samples from 101 
seizures) contained at least one SCRA. Full analytical data (GC-MS and UPLC-PDA-QToF-MS) for 
these samples is provided in the supplementary information. The findings are summarised in Table 1 
and the variation in concentrations of the five quantified SCRAs and the total SCRA concentration when 
multiple SCRAs were present in the same sample are shown in Figure 3. Of the 145 individual papers 
found to contain at least one SCRA, 40% (59 samples) contained 5F-MDMB-PICA (5) as a main 
component ranging in concentration from <0.08 ± 0.01 to 0.76 ± 0.11 mg/cm2 paper; 31% (45 samples) 
contained 4F-MDMB-BINACA (7) ranging in concentration from <0.09 ± 0.01  to 0.94 ± 0.14 mg/cm2 
paper; 29% (42 samples) contained 5F-MDMB-PINACA (5F-ADB) (3) ranging in concentration from 
<0.05 ± 0.01 to 1.17 ± 0.17 mg/cm2 paper; 15% (22 samples) contained MDMB-4en-PINACA (8), 
ranging in concentration from <0.07 ± 0.01  to 0.58 ± 0.09  mg/cm2 paper; 3% (5 samples) contained 
AMB-FUBINACA (4), ranging in concentration from 0.20 ± 0.03 to 1.16 ± 0.17 mg/cm2 paper; and 1% 
(1 sample) contained AMB-CHMICA (6) with a concentration of 0.58 ± 0.09 mg/cm2 paper. As far as 
the authors are aware this data represents the first time that SCRA concentrations in seized infused 
papers have been reported. 
 
Of these 146 samples, 23% (33 samples) contained multiple SCRAs with one sample seized in Prison 1 
on the 28th November 2018 found to contain four SCRAs: 5F-MDMB-PINACA (3) (major), CUMYL-
4CN-BINACA (10) (4.4% of 5F-MDMB-PINACA peak area), AMB-FUBINACA (4) (4.1%), and 5F-
MDMB-PICA (5) (1.7%). As no reference standard for CUMYL-4CN-BINACA (9) was available in 
our laboratory, this compound was identified by comparison of spectra (see supplementary electronic 
information) to published GC-MS and UPLC-QToF-MS data50-52, 54. In 11 cases, these other SCRAs 
were present in very minor proportions (<1% of major SCRA peak area) possibly indicating cross 
contamination prior to our analysis, whilst in 22 cases they were present in higher proportions, indicating 
more purposeful addition (Table 2). For example, in April and May 2019 there were two samples 
detected with an almost 50:50 proportion of 5F-MDMB-PINACA and 5F-MDMB-PICA and 73% (16 
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samples) of all MDMB-4en-PINACA detections also contained 4F-MDMB-BINACA as a major 
component. Where multiple SCRAs were detected in the same paper sample, their combined SCRA 
concentration remained within the concentration range calculated for single SCRAs. A plot of the total 
SCRA concentration in each sample as a function of seizure date is provided in the supplementary 
information.   
The timeline of the emergence of different SCRAs is provided in Figure 4. 5F-MDMB-PINACA (1) 
dominated between June and November 2018, but after this date, different compounds began to be 
detected including 5F-MDMB-PICA (5) in November 2018, which went on to become the most 
commonly detected SCRA in this dataset; 4F-MDMB-BINACA (7) in February 2019; a single sample 
containing AMB-CHMICA (6) in March 2019; and MDMB-4en-PINACA (8) in June 2019.  
 
5F-MDMB-PICA (5), 4F-MDMB-BINACA (7), and MDMB-4en-PINACA (8) detections increased 
over the time of the study and the number of samples in which multiple SCRAs were detected also 
increased. From the data presented, it seems clear that the introduction of legislative controls on the 
production and export of eight SCRAs, including 5F-MDMB-PINACA (3) and AMB-FUBINACA (4) 
by the People’s Republic of China on 29 August 2018, has led to their decreased prevalence and the 
emergence in Scottish prisons of structurally related indole/indazole-3-carboxamide SCRA compounds, 
all with similar synthetic routes to 5F-MDMB-PINACA (3), not covered by the ban (e.g. 5F-MDMB-
PICA (5), 4F-MDMB-BINACA (7), and MDMB-4en-PINACA (8)).  
 
In Europe, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) notified member 
states of the first seizures/identifications of 4F-MDMB-BINACA (7) in France and the Netherlands in 
October 2018 and in the UK in November 201855. It was detected in three seized herbal materials 
(seizure dates unknown) and one small piece of paper (seized following a positive 4F-MDMB-BINACA 
metabolite detection in a prison sample in January 2019) in Germany38. MDMB-4en-PINACA was first 
detected in a test purchase as part of the RESPONSE 2 project60 and notified to EU member states via 
the EU Early Warning System in August 201861.  
 
In the UK, 4F-MDMB-BINACA (7) was detected by the Welsh Emerging Drugs and Identification of 
Novel Substances (WEDINOS) service in December 2018 in samples of herbal materials and has also 
been detected in e-liquids for vaping, purporting to contain THC39. Between 14 December 2018 and 22 
November 2019, 94 detections of 4F-MDMB-BINACA have been reported by the service. Interestingly, 
WEDINOS have not, up to 2nd December 2019, reported any detections of 5F-MDMB-PICA (5) in 
publicly available data39 despite it being the most commonly detected SCRA in this study, indicating 
possible localised market differences. The first WEDINOS detection of MDMB-4en-PINACA was from 
a sample submitted on the 14th August 2019 and it has been detected in three further samples, all of 
which were detected with 4F-MDMB-BINACA, similar to the samples described in this study, possibly 
indicating a common source of materials (or market availability). 
 
Similar trends have been reported in the United States demonstrating a globalised market in SCRA 
production and export. Krotulski et al.56 described the first detection of 4F-MDMB-BINACA (7) in the 
United States in seized herbal material in December 2018 and note the substance was first also detected 
in November 2018 in Singapore56. Between November 2018 and March 2019, 4F-MDMB-BINACA (7) 
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was detected in 29 toxicology cases. The CFSRE NPS Discovery programme reported that between 
January 2019 and June 2019, 5F-MDMB-PICA (5) and 4F-MDMB-BINACA (7) were the most 
commonly detected SCRAs in casework57,58. Prior to that, as in our data, 5F-MDMB-PINACA (3) had 
been the most commonly detected compound with 5F-MDMB-PICA emerging in the third quarter of 
2018. CFSRE also reported their first detections of MDMB-4en-PINACA in forensic toxicology 
casework in samples collected in July 201959. In the United States Drug Enforcement Agency’s Special 
Testing and Research Laboratory’s Emerging Trends Program report for quarter 1 of 2019, 5F-MDMB-
PINACA (3) was the most commonly detected SCRA, followed by 5F-MDMB-PICA (5), which had 
begun to increase in prevalence from the third quarter of 2018. This programme has not, as of 1 July 
2019, reported any 4F-MDMB-BINACA (7) or MDMB-4en-PINACA (8) detections62-65.  
 
The evolution of the SCRA market in Scottish prisons could possibly be described as being relatively 
conservative, with little variability of compounds at any one time and emerging compounds having 
remained for some time almost exclusively within the indole/indazole-3-carboxamide structural class. 
It is difficult to predict which new compounds might appear next, however similar structural analogues 
such as AMB-4en-PICA (MMB-022; Methyl 3-methyl-2-[(1-pent-4-enylindole-3- 
carbonyl)amino]butanoate) and MDMB-4en-PICA (methyl-3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-
indole-3-carboxamido)butanoate) may be likely.  SCRAs most recently detected in the European early 
warning system (EWS) include the alkylcarboxyl-indazole-3-carboxamide APP-BINACA (N-(2-amino-
1-benzyl-2-oxo-ethyl)-1-butyl-indazole-3-carboxamide)66, which has also been detected in toxicology 
case samples in the United States, commonly alongside 4F-MDMB-BINACA67; CUMYL-CBMICA (1-
(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)-1H-indol-3-carboxamide)68 which is unusual in that it 
replaces the more commonly seen alkyl/fluorobenzyl ‘tail’ moiety with a cyclobutylmethyl ‘tail’ moiety; 
the adamantyl azaindole 5F-A-P7AICA (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxamide)69; 2F-QMPSB, a arylsulfonamide-based synthetic cannabinoid (quinolin-8-
yl 3-((4,4-difluoropiperidin-1-yl)sulfonyl)-4-methylbenzoate)70; and the naphthoylindole 5F-JWH-398 
(1-(5-fluoropentyl)-3-(4-chloro-1-naphthoyl)indole)71.  
 
All SCRAs detected in this study to date are known or expected to be potent CB1 agonists, however a 
range of different in vitro assays to determine CB1 and CB2 potency and efficacy have been used in the 
literature and direct comparisons should be made with caution72-74. Using a FLIPR assay which measures 
changes in membrane potential, Banister et al., (2016) reported similar CB1 EC50 values for 5F-MDMB-
PICA (5) and 5F-MDMB-PINACA (3) (0.45 and 0.59 nM respectively), both being more potent at CB1 
than AMB-FUBINACA (4) and AMB-CHMICA (6) (2.0 Nm and 3.5 nM respectively), and all were 
considerably more potent than ∆9-THC (171 nM)73. To the best of the author’s knowledge there is 
currently no publicly available data on the relative in vitro CB1 potency (and efficacy) of 4F-MDMB-
BINACA or MDMB-4en-PINACA as compared to structurally related compounds; however, based on 
existing structural-activity relationships they are highly likely to be potent CB1 receptor agonists. There 
is currently no information available regarding any ‘off-target’ receptor potency or efficacy of these 
substances or any studies to date on their non-CB receptor mediated effects. 
 
3.2. Impurity profiling 
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Several impurities were identified in some samples during the initial qualitative screening analysis. 
Three potential impurities were consistently found in 5F-MDMB-PICA (5) containing samples (spectra 
for these minor components are provided in the supplementary electronic information): a tentatively 
identified fluorinated PICA (0.4-18% of 5F-MDMB-PICA peak area, detected in 66% of the samples) 
and tentatively identified 5-fluoropentylindole impurity (0.16-0.35% of 5F-MDMB-PICA peak area), 
which may be either impurities or degradation products, and a tentatively identified 5Cl-MDMB-PICA 
(0.3-3.1% of 5F-MDMB-PICA peak area), which is likely a synthesis by-product. Five 4F-MDMB-
BINACA (7) samples also contained a tentatively identified 4Cl-MDMB-BINACA impurity as a minor 
component (0.1-1.26% of 4F-MDMB-BINACA peak area), likely to be a synthesis by-product. Five 5F-
MDMB-PINACA samples contained trace amounts of a tentatively identified 5Cl-MDMB-PINACA 
impurity, likely to be a synthesis by-product. Although often only very minor components, the 
tentatively identified impurities in the SCRA samples might, alongside chiral analysis, facilitate batch 
profiling.  
 
Two previous studies have noted degradation of SCRAs which may or not be analytical artifacts74,75: 
degradation of PB-22 (11) (quinolin-8-yl 1-pentyl-(1H-indole)-3-carboxylate), also known as QUPIC; 
FUB-PB-22 (12) (quinolin-8-yl 1-[(4-fluorophenyl)methyl]indole-3-carboxylate); 5F-PB-22 (13) 
(quinolin-8-yl 1-(5-fluoropentyl)indole-3-carboxylate); 5F-APICA (14) (N-(1-adamantyl)-1-(5-
fluoropentyl)indole-3-carboxamide), also known as STS-135; and 5F-APINACA (3) when in methanol 
or ethanol. It was discussed that the degradation could be thermal degradation during GC-MS analysis 
or just from the process of dissolution75,76 and this factor warrants further investigation, specifically for 
the potent and prevalent indole-3-carboxamide and indazole-3-carboxamides detailed in this study. 
Breakdown of these compounds in the GC liner over time was noted in this study, which was mitigated 
by changing the GC liner. 
 
In all four samples where AMB-FUBINACA (4) was present as the main SCRA, EMB-FUBINACA 
(10) was detected as a minor component (0.21-0.27% of AMB-FUBINACA peak area). In three of these 
samples, the synthetic cathinone 4F-PHP (1‐(4‐fluorophenyl)‐2‐(pyrrolidin‐1‐yl)hexanone) was 
tentatively identified by comparison to EI spectra in the Cayman spectral library and published MS/MS 
data71 (see Supplementary Information for spectra), twice as a minor component (<1.0%) in samples 
seized from Prison 1 (Figure 2(c)) and once as a major component (12.9% of the AMB-FUBINACA 
peak area) in a sample seized in Prison 3. To the best of the authors knowledge, there have been very 
few reports of synthetic cannabinoid/synthetic cathinone mixtures and none in seized infused papers. 
Recently, there was a report of the synthetic cathinone N-ethylpentylone found in combination with 
synthetic cannabinoids in post-mortem urine in four prisoners from Florida between March 2017 and 
November 201838. While SCRAs have been reported to enter prisons in Florida via impregnated paper, 
it is unclear from the results of post-mortem urine testing if the mixture was on the paper or if the SCRAs 
and synthetic cathinones were taken separately. These tentatively identified mixtures, impurities and by-
products, along with chiral profiling, may prove useful in future batch profiling studies. 
 
3.3. Concentration mapping across seized SCRA infused papers 
A typical dose of SCRA infused paper appears to be approximately 1cm2 (Figure 2(d)). This size of 
paper will fit between the e-liquid cartridge and the heating element in an e-cigarette. There is also 
evidence that, where available, users will utilise paper punches to create circular dosage units, with this 
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format fitting better into the e-cigarettes than the squares (Figure 2(d-f)). Such samples are easy to 
conceal, transport, and exchange between prisoners.  
 
Two larger seized paper samples, from which doses would be created, were selected for a detailed study 
of SCRA concentration variation across single sheets of paper to indicate the variability of doses from 
that sheet of paper. The first sample comprised a dark coloured greetings card with two pieces of white 
card on the inside (Figure 6a). Both pieces of white card, measuring approximately 150x105 cm2, bore 
visible brown coloured wash marks. One piece of white card was selected at random and a total of 163 
individual hole-punched samples were collected using an overlaid 1cm2 grid and the AMB-CHMICA 
(6) concentrations determined as previously described. The data is summarised using a concentration 
heat map (Figure 6b) and shows that there was significant variation of concentrations across the card, 
ranging from 0.47-2.38 mg/cm2. The highest concentrations were in the middle of the card and the lowest 
concentrations tended to be in the corners. In this case, the SCRA containing solution used to prepare 
the card was most likely added to the centre and the AMB-CHMICA (6) containing solution moved 
outwards as the solvent travelled through the paper and evaporated. 
 
In contrast, there was no visible staining on the pieces of paper from the second sample which had 
previously been shown during qualitative analysis to contain 5F-MDMB-PICA (5). The sample 
comprised 12 separate pieces of white paper of varying sizes with black inked handwriting on one side 
(Figure 7a). Through visual comparison, all 12 pieces were found to have originated from the same 
letter; however, only six of the pieces formed a physical fit, with the handwriting on these six pieces 
continuing from the adjacent piece of paper. These six pieces of paper were selected for concentration 
mapping (Figure 7b). In total, 208 individual quantitative analyses were carried out, taking one hole-
punch sample of paper per cm2 and the samples quantitatively analysed. The resultant heat map (Figure 
8c) shows a variable distribution of 5F-MDMB-PICA (5) across the letter, with the lowest concentration 
in square ‘N2’ at 0.48 mg/cm2 and the highest concentration in square ‘B1’ at 1.34 mg/cm2 (Figure 7c). 
The highest concentrations were detected in one corner of the paper (if all the paper pieces are considered 
as a single sheet) consistent with the paper having been soaked and then held at one corner to drip dry 
and then dried flat or held at one corner and dried hanging up). 
 
To demonstrate the influence of the SCRA infusion and drying method on SCRA distribution across 
paper, a controlled SCRA paper dosing experiment was carried out using a 5F-MDMB-PINACA (6) 
solution in ethanol. The distribution of 5F-MDMB-PINACA (6) in the dried papers (Figure 8) was less 
variable when the infused papers were laid flat to dry, compared to when they were hung up to dry. In 
the samples that were hung up to dry, concentrations at the bottom of the papers were considerably 
higher than the top sections. This clearly demonstrates the influence of preparation method on SCRA 
concentration variability across sheets of paper.  
 
SCRA heterogeneity has been reported previously in SCRA infused herbal samples23,75,76 leading to 
inconsistent dosing, increasing the likelihood of users experiencing unpredictable effects. In such 
samples, this variability can be mitigated somewhat by mixing or shaking the herbal material prior to 
smoking, however this is not possible with an infused paper. The data presented in this study clearly 
shows that SCRA concentrations can vary considerably across a single sheet of paper, which will then 
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be cut into a series of smaller dosage units and users may be unaware of this variability. This increases 
the inherent risks of using papers infused with potent psychoactive substances such as SCRAs compared 
to other available forms of the drug. The variation of SCRA concentrations across sheets of paper also 
demonstrates the need for careful sampling of seized paper samples (especially for larger pieces of 
paper). Although this study utilised a single hole punch sample for analysis, it is recommended in future 
that multiple samples are taken from across the paper surface to provide a more representative SCRA 
concentration estimate.  
 
Taking a pragmatic harm reduction-focussed view, preparing SCRA infused papers in a manner that 
minimises concentration gradients across the paper would at least allow for more consistent dosing 
across a single sheet. In the short- to medium-term, the implementation of mail scanning using ion 
mobility spectrometer (IMS) systems and copying procedures for SCRAs may be effective in reducing 
the supply of infused papers into prisons via the mail system; however, the supply chain may respond 
in a variety of ways which may or may not increase harms. For this reason, continued and responsive 
vigilance is required to maintain our understanding of the SCRA market in prisons and continue to 
improve harm reduction services. 
 
4. Conclusions 
Methods for the qualitative and quantitative analysis of SCRA infused papers using GC-MS and UPLC-
PDA-QToF-MS were developed, validated, and successfully applied to 354 non-judicial paper samples 
seized from three Scottish prisons between June 2018 and September 2019. Our analysis has confirmed 
that SCRA infused papers, designed to evade detection and facilitate smuggling, are currently circulating 
and are highly prevalent within Scottish prisons and both the nature of the substances present and their 
concentrations are variable both between paper samples and across individual sheets. SCRA 
concentrations across the whole of two papers studied in detail varied by up to a factor of seven across 
an individual sheet with the variation due to the methods in which the papers were prepared and dried. 
A clear change in SCRA prevalence from 5F-MDMB-PINACA (3) and AMB-FUBINACA (4) to 5F-
MDMB-PICA (5) and 4F-MDMB-BINACA (7) was observed following the legislative control of 5F-
MDMB-PINACA (3) and AMB-FUBINACA (4) in the People’s Republic of China in August 2018, 
similar to changes noted recently in other jurisdictions worldwide. The evolution of the SCRA market 
in Scottish (and according to available data, wider UK) prisons, could be described as being relatively 
conservative, with little variability of compounds at any one time and emerging compounds for some 
time remaining almost exclusively within the indole/indazole-3-carboxamide structural class. Continued 
vigilance is required to track market trends of SCRAs whilst also taking all steps to reduce supply by 
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A summary of the synthetic cannabinoid receptor agonist (SCRA) detected and their concentration 
ranges in 108 SCRA infused papers from 3 Scottish prisons 
Compound n  
% 
of SCRA positive 





5F-MDMB-PICA (5) 50 41 (59) <0.08 – 0.76 
5F-MDMB-PINACA (3) 39  29 (42) <0.05 – 1.17 
4F-MDMB-BINACA (7) 40  31 (45) <0.09 – 0.94 
AMB-FUBINACA (4) 3 3 (5) 0.20 – 1.16 
MDMB-4en-PINACA (8) 19  15 (22) <0.07 – 0.58 
AMB-CHMICA (6) 1 1 (1) 0.58* 
















Table 2 Samples containing multiple synthetic cannabinoid receptor agonists (SCRAs) 
 























FL19/ 0067-2 23/11/18 5F-MDMB-PINACA - 4.11 1.67 - - - 4.38 - 
FL19/ 0078-2 11/02/19 4F-MDMB-BINACA 3.94 - 5.70 - - - - - 
FL19/ 0110 28/04/19 5F-MDMB-PINACA - - 82.4-87.5 - - - - - 
FL19/ 0111-5 01/05/19 5F-MDMB-PICA 66.9 -  - - - - - - 
FL19/ 0127 07/06/19 4F-MDMB-BINACA - - - - 54.7 35.5 - - 
FL19/ 0138-2 25/06/19 4F-MDMB-BINACA - - 16.2 - - - - - 
FL19/ 0142 17/06/19 MDMB-4en-PINACA - - - 4.5 - - - - 
FL19/ 0146 04/05/19 4F-MDMB-BINACA - - 17.6 - - - - - 
FL19/ 0150 09/06/19 MDMB-4en-PINACA - - - 51.4 - - - - 
FL19/ 0196 30/08/19 4F-MDMB-BINACA - - - - - - - 48.5 
FL19/ 0205 13/09/19 4F-MDMB-BINACA - - - - - - - 48.7 
FL19/ 0206-C 03/09/19 4F-MDMB-BINACA - - - - - - - 68.0 
FL19/ 0206-D 03/09/19 4F-MDMB-BINACA - - - - - - - 81.4 
FL19/ 0206-F 03/09/19 4F-MDMB-BINACA - - - - - - - 55.1 
FL19/ 0207-2 07/08/19 5F-MDMB-PICA - - - 2.5 - - - - 
FL19/ 0210 18/09/19 4F-MDMB-BINACA - - 44.1 - - - - 84.7 
FL19/ 0215-E 18/09/19 4F-MDMB-BINACA - - - - - - - 75.4 
FL19/ 0215-F 18/09/19 4F-MDMB-BINACA - - 24.1 - - - - 76.4 
FL19/ 0215-G 18/09/19 4F-MDMB-BINACA - - - - - - - 70.8 
FL19/ 0224-1 04/09/19 4F-MDMB-BINACA - - TRACE - - - - 38.4 
FL19/ 0224-2 04/09/19 4F-MDMB-BINACA - - TRACE - - - - 0.3 
FL19/ 0232-2 23/09/19 4F-MDMB-BINACA - - - - - - - 74.7 
 









Figure 1   
Relevant synthetic cannabinoid receptor agonist (SCRA) molecular structures: (1) 5F-APINACA (5F-AKB48); 
(2) MDMB-CHMICA;   (3) 5F-MDMB-PINACA (5F-ADB); (4) AMB-FUBINACA; (5) 5F-MDMB-PICA; (6) 
AMB-CHMICA; (7) 4F-MDMB-BINACA; (8) MDMB-4en-PINACA; (9)  CUMYL-4CN-BINACA; (10) EMB-
FUBINACA; (11) PB-22 (QUPIC); (12) FUB-PB-22; (13) 5F-PB-22; and (14) 5F-APICA (STS-135). 
Figure 2  
Examples of seized items submitted for synthetic cannabinoid receptor agonist (SCRA) analysis. 
(a) paper sample FL19/0077; (b) paper sample FL19/0064; (c) multi-part paper sample FL19/0149; (d) 
a typical single dose (approx. 1cm2) paper sample, FL19/0111-7; (e) sample FL19/0082: paper stuck to 
underside of stuck together milk bottle labels, most likely to facilitate exchange of a SCRA paper dosage 
unit; (f) sample FL19/0091: Disassembled e-cigarette seized with papers   
Figure 3  
Concentrations of the main synthetic cannabinoid in the infused paper samples from three Scottish 
prisons found positive for one or more synthetic cannabinoid (n=132*). 
 
* 14 samples were not quantified as they were only present at trace levels in the qualitative analysis or 
not enough sample was remaining for quantitative analysis.   
 
Figure 4  
Timeline of the main synthetic cannabinoid concentrations of all quantitated samples with a seizure date 
from three Scottish prisons (n=137) where error bars represent the estimated error of 15% from the 
method validation performed. Any samples on the x-axis (indicating a concentration of 0) had 
concentrations below the limit of quantitation (<0.05-0.09 mg/cm2). 
 
Figure 5  
(a) Sample FL19/0097: greetings card with white card in interior; (b) AMB-CHMICA concentration 
mapping across paper (white squares in opposite corners indicate positions of samples taken for initial 
qualitative (screening) analysis).  
 
Figure 6  
(a) Sample FL19/0100 from Prison 1: cut up note; (b) cut up note showing positions of six pieces which 
formed a physical fit and were used in the 5F-MDMB-PICA concentration mapping; (c) 5F-MDMB-
PICA concentration mapping across paper (white squares indicate positions of samples taken for initial 
qualitative (screening) analysis).  
 
Figure 7 Laboratory prepared SCRA infused paper samples. Six 25cm2 pieces of lined notepaper were 
placed flat in 5 mL of an approximately 4 mg/mL solution of (R)-5F-MDMB-PINACA for 
approximately 10 seconds. Replicate samples A1-3 were removed from the solution and dried flat for 
one hour. Replicate samples B1-3 were removed from the solution and hung up to dry for one hour 
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